Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

New Synthetic Cannabinoids Metabolism and Strategies to Best Identify Optimal Marker Metabolites
Xingxing Diao, Marilyn A. Huestis
Frontiers in Chemistry (2019) Vol. 7
Open Access | Times Cited: 118

Showing 26-50 of 118 citing articles:

Urinary Metabolite Biomarkers for the Detection of Synthetic Cannabinoid ADB-BUTINACA Abuse
Chi Hon Sia, Ziteng Wang, Evelyn Mei Ling Goh, et al.
Clinical Chemistry (2021) Vol. 67, Iss. 11, pp. 1534-1544
Open Access | Times Cited: 23
Comparison of Tissue Abundance of Non-Cytochrome P450 Drug-Metabolizing Enzymes by Quantitative Proteomics between Humans and Laboratory Animal Species
Abdul Basit, Peter W. Fan, S. Cyrus Khojasteh, et al.
Drug Metabolism and Disposition (2021) Vol. 50, Iss. 3, pp. 197-203
Open Access | Times Cited: 23
Wastewater analysis of psychoactive drugs: Non-enantioselective vs enantioselective methods for estimation of consumption
Ivan Langa, Ricardo Gonçalves, Maria Elizabeth Tiritan, et al.
Forensic Science International (2021) Vol. 325, pp. 110873-110873
Closed Access | Times Cited: 22
A Systematic Study of the In Vitro Pharmacokinetics and Estimated Human In Vivo Clearance of Indole and Indazole-3-Carboxamide Synthetic Cannabinoid Receptor Agonists Detected on the Illicit Drug Market
Andrew M. Brandon, Lysbeth H. Antonides, Jennifer Riley, et al.
Molecules (2021) Vol. 26, Iss. 5, pp. 1396-1396
Open Access | Times Cited: 21
SystematicIn VitroMetabolic Profiling of the OXIZID Synthetic Cannabinoids BZO-4en-POXIZID, BZO-POXIZID, 5F-BZO-POXIZID, BZO-HEXOXIZID and BZO-CHMOXIZID
Shimpei Watanabe, Steven Baginski, Takahiro Iwai, et al.
Journal of Analytical Toxicology (2023) Vol. 47, Iss. 5, pp. 455-463
Closed Access | Times Cited: 8
The metabolic profile of the synthetic cannabinoid receptor agonist ADB-HEXINACA using human hepatocytes, LC–QTOF-MS and synthesized reference standards
Steven Baginski, Tobias Rautio, Lorna A. Nisbet, et al.
Journal of Analytical Toxicology (2023) Vol. 47, Iss. 9, pp. 826-834
Open Access | Times Cited: 8
Paving the way for small-molecule drug discovery.
Yu‐Shui Ma, Rui Xin, Xiao‐Li Yang, et al.
American Journal of Translational Research (2021) Vol. 13, Iss. 3, pp. 853-870
Closed Access | Times Cited: 18
Recent advances in identifying and utilizing metabolites of selected doping agents in human sports drug testing
Mario Thevis, Thomas Piper, Andreas Thomas
Journal of Pharmaceutical and Biomedical Analysis (2021) Vol. 205, pp. 114312-114312
Closed Access | Times Cited: 18
Detection and phase I metabolism of the 7‐azaindole‐derived synthetic cannabinoid 5F‐AB‐P7AICA including a preliminary pharmacokinetic evaluation
Arianna Giorgetti, Lukas Mogler, Belal Haschimi, et al.
Drug Testing and Analysis (2019) Vol. 12, Iss. 1, pp. 78-91
Open Access | Times Cited: 21
Metabolite identification of iridin in rats by using UHPLC-MS/MS and pharmacokinetic study of its metabolite irigenin
Tao Hu, Xinyu Ge, Junyang Wang, et al.
Journal of Chromatography B (2021) Vol. 1181, pp. 122914-122914
Closed Access | Times Cited: 16
Cannabinoids and Neurogenesis: The Promised Solution for Neurodegeneration?
Andrea Valeri, Emanuela Mazzon
Molecules (2021) Vol. 26, Iss. 20, pp. 6313-6313
Open Access | Times Cited: 16
In-depth comparison of the metabolic and pharmacokinetic behaviour of the structurally related synthetic cannabinoids AMB-FUBINACA and AMB-CHMICA in rats
David Fabregat‐Safont, María Mata-Pesquera, Manuela Barneo‐Muñoz, et al.
Communications Biology (2022) Vol. 5, Iss. 1
Open Access | Times Cited: 12
In vitro and in vivo metabolic study of three new psychoactive β-keto-arylcyclohexylamines
Linhao Xu, Hui Yan, Yiling Tang, et al.
Journal of Analytical Toxicology (2024) Vol. 48, Iss. 4, pp. 217-225
Closed Access | Times Cited: 2
Pyrrolidinyl Synthetic Cathinones α-PHP and 4F-α-PVP Metabolite Profiling Using Human Hepatocyte Incubations
Jérémy Carlier, Xingxing Diao, Raffaele Giorgetti, et al.
International Journal of Molecular Sciences (2020) Vol. 22, Iss. 1, pp. 230-230
Open Access | Times Cited: 17
Detection of the Synthetic Cannabinoids AB-CHMINACA, ADB-CHMINACA, MDMB-CHMICA, and 5F-MDMB-PINACA in Biological Matrices: A Systematic Review
Elisabet Navarro‐Tapia, Jana Codina, Víctor José Villanueva‐Blasco, et al.
Biology (2022) Vol. 11, Iss. 5, pp. 796-796
Open Access | Times Cited: 11
Human phase‐I metabolism and prevalence of two synthetic cannabinoids bearing an ethyl ester moiety: 5F‐EDMB‐PICA and EDMB‐PINACA
Arianna Giorgetti, Pietro Brunetti, Belal Haschimi, et al.
Drug Testing and Analysis (2022) Vol. 15, Iss. 3, pp. 299-313
Open Access | Times Cited: 11
New Psychoactive Substances: Which Biological Matrix Is the Best for Clinical Toxicology Screening?
Lea Wagmann, Cathy M. Jacobs, Markus R. Meyer
Therapeutic Drug Monitoring (2022) Vol. 44, Iss. 5, pp. 599-605
Closed Access | Times Cited: 10
The role of microorganisms in the biotransformation of psychoactive substances and its forensic relevance: a critical interdisciplinary review
Eduardo Geraldo de Campos, Otávio Guilherme Gonçalves de Almeida, Elaine Cristina Pereira De Martinis
Forensic Sciences Research (2023) Vol. 8, Iss. 3, pp. 173-184
Open Access | Times Cited: 6
In vitro metabolic profiling of new synthetic cannabinoids, ADB-FUBIATA, AFUBIATA, CH-FUBIATA, and CH-PIATA
Shimpei Watanabe, Hiroshi Yamane, Takahiro Iwai, et al.
Archives of Toxicology (2023) Vol. 97, Iss. 12, pp. 3085-3094
Closed Access | Times Cited: 6
Monitoring metabolism of synthetic cannabinoid 4F-MDMB-BINACA via high-resolution mass spectrometry assessed in cultured hepatoma cell line, fungus, liver microsomes and confirmed using urine samples
Huey Sze Leong, Shimpei Watanabe, Unnikrishnan Kuzhiumparambil, et al.
Forensic Toxicology (2020) Vol. 39, Iss. 1, pp. 198-212
Open Access | Times Cited: 16
Metabolism of MMB022 and identification of dihydrodiol formation in vitro using synthesized standards
Shimpei Watanabe, Xiongyu Wu, Johan Dahlén, et al.
Drug Testing and Analysis (2020) Vol. 12, Iss. 10, pp. 1432-1441
Open Access | Times Cited: 15
The Future of Analytical and Interpretative Toxicology: Where are We Going and How Do We Get There?
Sarah M.R. Wille, Simon Elliott
Journal of Analytical Toxicology (2020) Vol. 45, Iss. 7, pp. 619-632
Open Access | Times Cited: 15
Recent trends in drugs of abuse metabolism studies for mass spectrometry–based analytical screening procedures
Lea Wagmann, Tanja M. Gampfer, Markus R. Meyer
Analytical and Bioanalytical Chemistry (2021) Vol. 413, Iss. 22, pp. 5551-5559
Open Access | Times Cited: 14
Cannabinoids modulate food preference and consumption in Drosophila melanogaster
Jianzheng He, Alice Mei Xien Tan, Si Yun Ng, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 13
Analytical Methodologies for the Characterization and Analysis of the Parent Compound and Phase I Metabolites of 4F-MDMB-BICA in Human Microsome, Urine and Blood Samples
Tímea Körmöczi, Éva Sija, László Institóris, et al.
Journal of Analytical Toxicology (2021) Vol. 46, Iss. 2, pp. 135-145
Open Access | Times Cited: 13

Scroll to top